A Quote by Kathy Giusti

In 15 years, we've raised $225 million, sequenced the myeloma genome, and opened 45 trials of 23 drugs - six approved by the FDA - which have doubled the life span of multiple myeloma patients. I've taken both Velcade and Revlimid, which we helped develop.
Patients who face long odds and terminal illnesses do not always have access to the latest drugs in clinical trials. They don't want to give up, but they don't have years to wait for new drugs to receive FDA approval.
Consider the clinicaltrials by which drugs are tested in human subjects.5 Before a new drug can enter the market, its manufacturer must sponsor clinicaltrials to show the Food and Drug Administration that the drug is safe and effective, usually as compared with a placebo or dummy pill. The results of all the trials (there may be many) are submitted to the FDA, and if one or two trials are positive—that is, they show effectiveness without serious risk—the drug is usually approved, even if all the other trials are negative.
I knew what leukemia and lymphoma were, but I had never heard of multiple myeloma.
The question is, are there useful things that we can do with the results of a genome sequence that would bring benefit? And the answer is, today, should the majority of people go and have their genome sequenced? Probably not. But are there particular circumstances in which genome sequencing is really helpful? Yes, there are.
I'm happy to say that I am in remission. That R word is something critically important to cancer patients, especially in a disease like myeloma. But I never lose sight of the fact that there is another R word called relapse.
When the FDA forces an old drug off the market, patients have very little say in the matter. Patients have even less of a say when the FDA chooses not to approve a new drug. Instead, we are supposed to rely on the FDA's judgment and be grateful. But can the FDA really make a choice that is appropriate for everyone? Of course not.
Geraldine Ferraro, the first woman to run for vice president, died from multiple myeloma. Frank Reynolds, the ABC anchorman, who I had talked to toward the end of his life, not knowing what he had, died from it. Later I found out that Frank McGee, who was the Today Show host, died from it.
I have had my genome fully sequenced and have learned a great deal about which medications I would respond to and which might or would induce major side effects, along with knowing many medical conditions for which I'm particularly susceptible.
Despite the fact that one in every two men and one in every three women will be diagnosed with cancer in their lifetime, no one ever expects it to happen to them. I surely didn't. I was an otherwise healthy 37-year-old when I was diagnosed in 1996 with multiple myeloma, the same rare cancer Tom Brokaw has.
Here's a startling fact: in the 45 years since the introduction of the automated teller machine, those vending machines that dispense cash, the number of human bank tellers employed in the United States has roughly doubled, from about a quarter of a million to a half a million.
Within the last three years the amount of classified materials has doubled to 15.6 million decisions to classify documents.
When I was 23, I founded an organization called Dress for Success, which is now in more than 100 cities in 8 countries and has helped a million women transition from welfare to work.
My goals over the decade include to develop new drugs to treat intractable diseases by using iPS cell technology and to conduct clinical trials using it on a few patients with Parkinson's diseases, diabetes or blood diseases.
In 2005, a man diagnosed with multiple myeloma asked me if he would be alive to watch his daughter graduate from high school in a few months. In 2009, bound to a wheelchair, he watched his daughter graduate from college. The wheelchair had nothing to do with his cancer. The man had fallen down while coaching his youngest son's baseball team.
In 1975, the respected British medical journal Lancet reported on a study which compared the effect on cancer patients of (1) a single chemotherapy, (2) multiple chemotherapy, and (3) no treatment at all. No treatment 'proved a significantly better policy for patients' survival and for quality of remaining life.'
Patients are becoming aware that they're being taken for a ride by big pharma companies. They charge high prices and have never cared for India's healthcare. There are 23 million cases of cancer every year and India has a fair share of that.
This site uses cookies to ensure you get the best experience. More info...
Got it!